Severe clinical outcomes amongst infants treated with primaquine in Papua were rare.
Few children received PQ treatment during the second visit to HFs following diagnosis of potential non-falciparum malaria.
The goal to eliminate malaria from the Asia-Pacific by 2030 will require the safe and widespread delivery of effective radical cure of malaria.
Phenotypic and genotypic analyses both detected low prevalence of G6PD deficiency and the CYP2D6*4 variants.
Primaquine (PQ) is the only commercially available drug that clears dormant liver stages of malaria and blocks transmission to mosquito vectors.
T14 was effective for opportune elimination of the primary blood infection and preventing relapse episodes.